AbbVie Completes $1.4B Acquisition of Aliada Therapeutics

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Brookfield Asset Management and CDPQ Acquire Antylia Scientific from GTCR

May 28, 2025

Medical Devices

Brookfield Asset Management's private equity business, together with Brookfield Business Partners and CDPQ, completed the acquisition of Antylia Scientific from GTCR for approximately $1.3–$1.34 billion. Antylia, headquartered in Vernon Hills, Illinois, is a diversified life‑sciences tools manufacturer and distributor serving biopharma, clinical diagnostics and environmental testing markets; the transaction represents a PE exit after a decade of GTCR partnership and transformational growth.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Healthcare Services

AbbVie agreed to acquire Nimble Therapeutics for $200 million in cash, aiming to add Nimble’s preclinical oral peptide IL23R inhibitor pipeline and its proprietary peptide synthesis, screening, and optimization platform. AbbVie completed the acquisition in January 2025, incorporating Nimble into its operations and strengthening its immunology/R&D capabilities.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

AbbVie Acquires Celsius Therapeutics

June 27, 2024

Biotechnology

AbbVie has acquired Celsius Therapeutics, a Cambridge-based clinical-stage biotechnology company, for $250 million in cash. The acquisition adds Celsius' lead anti-TREM1 antibody candidate CEL383 to AbbVie’s inflammatory disease pipeline to support development for inflammatory bowel disease (IBD).

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.